MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-24-2026
Globus Medical Net Debt 2011-2026 | GMED
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Globus Medical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -511 M | -774 M | -455 M | - | - | - | -195 M | -140 M | -119 M | -133 M | -60.2 M | -82.3 M | -90 M | -212 M | -143 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -60.2 M | -774 M | -243 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Medical devices industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aziyo Biologics
AZYO
|
1.36 M | - | 1.37 % | $ 20.5 M |  USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
38.7 M | - | - | $ 1.77 B | USA |
 |
Conformis
CFMS
|
-26.2 M | - | - | $ 16.4 M | USA |
 |
Cardiovascular Systems
CSII
|
-64.6 M | - | 0.15 % | $ 844 M | USA |
 |
Cutera
CUTR
|
-140 M | - | -10.19 % | $ 1.99 M | USA |
 |
Bruker Corporation
BRKR
|
1.91 B | $ 38.78 | -1.25 % | $ 5.78 K | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
6.46 M | - | -5.86 % | $ 30.6 M | USA |
 |
Acutus Medical
AFIB
|
14.2 M | - | -26.83 % | $ 2.62 M | USA |
 |
Dynatronics Corporation
DYNT
|
1.8 M | - | 14.99 % | $ 929 K | USA |
 |
Eargo
EAR
|
-97.8 M | - | - | $ 10.2 M | USA |
 |
Allied Healthcare Products
AHPI
|
-3.31 M | - | 3.58 % | $ 2.21 M | USA |
 |
Cognyte Software Ltd.
CGNT
|
-47.4 M | $ 8.15 | 4.22 % | $ 585 M |  Israel |
 |
Second Sight Medical Products
EYES
|
961 K | - | -0.97 % | $ 54.4 M | USA |
 |
AdaptHealth Corp.
AHCO
|
1.64 B | $ 9.69 | 3.09 % | $ 1.31 B | USA |
 |
Apollo Endosurgery
APEN
|
-22.5 M | - | - | $ 475 M | USA |
 |
EDAP TMS S.A.
EDAP
|
-22.8 M | $ 4.15 | 4.01 % | $ 155 M |  France |
 |
Electromed
ELMD
|
-10.5 M | $ 24.26 | 1.17 % | $ 205 M | USA |
 |
CONMED Corporation
CNMD
|
802 M | $ 43.13 | -0.43 % | $ 1.34 B | USA |
 |
CryoLife, Inc.
CRY
|
230 M | - | -4.14 % | $ 702 M | USA |
 |
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | USA |
 |
FONAR Corporation
FONR
|
-42.8 M | $ 18.51 | 0.05 % | $ 121 M | USA |
 |
AxoGen
AXGN
|
15.2 M | $ 29.17 | -2.21 % | $ 1.34 B | USA |
 |
Apyx Medical Corporation
APYX
|
-10.1 M | $ 3.31 | 4.42 % | $ 115 M | USA |
 |
Axonics Modulation Technologies
AXNX
|
-230 M | - | - | $ 3.31 B | USA |
 |
Soliton, Inc.
SOLY
|
-31.6 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.02 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
-2.3 M | - | 0.03 % | $ 1.58 B | Israel |
 |
Accuray Incorporated
ARAY
|
73.7 M | $ 0.53 | 0.68 % | $ 54.5 M | USA |
 |
Misonix, Inc.
MSON
|
5.72 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
-4.95 M | - | - | $ 111 M |  Canada |
 |
Medigus Ltd.
MDGS
|
-6.43 M | - | 10.28 % | $ 55.5 M | Israel |
 |
Cytosorbents Corporation
CTSO
|
11.2 M | $ 0.79 | -1.24 % | $ 43 M | USA |
 |
Align Technology
ALGN
|
-925 M | $ 183.14 | 0.27 % | $ 13.7 B | USA |
 |
Intersect ENT, Inc.
XENT
|
50.8 M | - | - | $ 955 M | USA |
 |
Inari Medical
NARI
|
-27.9 M | - | - | $ 4.23 B | USA |
 |
Butterfly Network
BFLY
|
-65.9 M | $ 3.99 | 7.7 % | $ 845 M | USA |
 |
BIOLASE
BIOL
|
6.1 M | - | -13.19 % | $ 166 K | USA |
 |
Abbott Laboratories
ABT
|
1.65 B | $ 113.59 | 0.01 % | $ 198 B | USA |
 |
NuVasive
NUVA
|
-238 M | - | - | $ 2.07 B | USA |
 |
Nevro Corp.
NVRO
|
93.4 M | - | - | $ 217 M | USA |
 |
InMode Ltd.
INMD
|
-34.8 M | $ 13.58 | -0.18 % | $ 878 M | Israel |
 |
BioSig Technologies
BSGM
|
252 K | - | 37.08 % | $ 85.7 M | USA |
 |
Boston Scientific Corporation
BSX
|
9.26 B | $ 72.75 | -1.49 % | $ 108 B | USA |
 |
IRadimed Corporation
IRMD
|
-52.1 M | $ 105.22 | 0.89 % | $ 1.33 B | USA |
 |
IRIDEX Corporation
IRIX
|
-4.29 M | $ 1.42 | -0.7 % | $ 22.9 M | USA |
 |
Helius Medical Technologies
HSDT
|
-5.12 M | $ 2.31 | 16.67 % | $ 1.4 M | USA |
 |
Alphatec Holdings
ATEC
|
347 M | $ 13.05 | 0.23 % | $ 1.96 B | USA |
 |
Edwards Lifesciences Corporation
EW
|
-2.32 B | $ 85.73 | 0.55 % | $ 50.1 B | USA |